Ebenbuild erhält öffentliche Förderung im Rahmen des UBIC-Konsortiums für das Projekt "Digital Lung Twin“
28 nov. 2023 04h00 HE
|
AKAMPION
Bundesministerium für Bildung und Forschung (BMBF) bewilligt Fördermittel in Höhe von bis zu 1,8 Millionen Euro München, Deutschland, 28. November 2023 -- Ebenbuild, ein Unternehmen, das...
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
28 nov. 2023 04h00 HE
|
AKAMPION
Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF Munich, Germany, November 28, 2023 -- Ebenbuild, a company developing personalized, AI-driven...
Spexis to host business update conference call on October 9, 2023
06 oct. 2023 01h30 HE
|
Spexis AG
Spexis to host business update conference call on October 9, 2023
Spexis provides business update and announces financial results for the first half of 2023
29 sept. 2023 01h30 HE
|
Spexis AG
Spexis provides business update and announces financial results for the first half of 2023
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
28 sept. 2023 01h30 HE
|
Spexis AG
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
AI in Respiratory Diseases Market is Booming and Expected to Grow at a CAGR of 29.4% to 2031 | InsightAce Analytic
26 sept. 2023 05h05 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ,, Sept. 26, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI in Respiratory Diseases Market- (By...
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
15 août 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
30 juin 2023 01h15 HE
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
Global Asthma & COPD Therapies Market Report 2023-2033: Expansion into Emerging Markets to Offer Lucrative Growth Opportunities
28 juin 2023 04h38 HE
|
Research and Markets
Dublin, June 28, 2023 (GLOBE NEWSWIRE) -- The "Asthma & COPD Therapies Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.The Asthma & COPD Therapies Market...
DirectRx Takes the Lead in Lung Health for Patients Nationwide
07 juin 2023 06h23 HE
|
DirectRx Pharmacy
TROY, Mich., June 07, 2023 (GLOBE NEWSWIRE) -- DirectRx, a leading national specialty pharmacy dedicated to serving individual patients with complex and chronic health needs, has launched a new...